Navidea Biopharmaceuticals Investor Presentation — January 2021

Document content

January2021NavideaBiopharmaceuticals,Inc.2021AllRightsReservedNavideaBiopharmaceuticals,Inc.1Disclaimer

NavideaBiopharmaceuticals,Inc.2Theprivatesecuritieslitigationreformactof1995(theact)providesasafeharborforforward-lookingstatementsmadebyoronbehalfofthecompany.Statementsinthispresentation,whichrelatetootherthanstrictlyhistoricalfacts,suchasstatementsabouttheCompany’splansandstrategies,expectationsforfuturefinancialperformance,newandexistingproductsandtechnologies,anticipatedclinicalandregulatorypathways,andmarketsfortheCompany’sproductsareforward-lookingstatementswithinthemeaningoftheAct.Thewords“believe,”“expect,”“anticipate,”“estimate,”“project,”“forecast”,“goal”“future”,“intent”,“will”,“may”,”could”andsimilarexpressions,aswellasthenegativesoftheewordsorcomparablewords,identifyforward-lookingstatementsthatspeakonlyasofthedatehereof.Youarecautionedthatsuchstatementsinvolverisksanduncertaintiesthatcouldcauseactualresultstodiffermateriallyfromhistoricaloranticipatedresultsduetomanyfactorsincluding,butnotlimitedto,theCompany’scontinuingoperatinglossesanduncertaintyoffutureprofitability,uncertaintyofmarketacceptanceofitsproductsrelianceonthirdpartymanufacturers,accumulateddeficit,futurecapitalneeds,uncertaintyofcapitalfunding,dependenceonlimitedproductlineanddistributionchannels,competition,limitedmarketingandmanufacturingexperience,ourabilitytosuccessfullycompleteresearchandfurtherdevelopmentofourdrugcandidates,thetimingcost,anduncertaintyofobtaininganyrequiredregulatoryapprovalsofourdrugcandidates,ourabilitytosuccessfullycommercializeourdrugcandidates,andotherrisksdetailedintheCompany’smostrecentAnnualReportonForm10-KandotherSecuritiesandExchangeCommissionfilings.Youarefurthercautionedthattheforegoinglistofimportantfactorsisnotexclusive.TheCompanyundertakesnoobligationtopubliclyupdateorreviseanyforward-lookingstatements.3Weareaprecisionimmuno-diagnosticsandtherapeuticscompanyfocusedonsolvingthemanyproblemspresentedbyinflammatoryconditionsWeareleveragingourplatformtechnologytocreatearobustpipelineofimmuno-diagnosticsandimmuno-therapeutics

NavideaBiopharmaceuticals,Inc.4Aprecisionimmuno-diagnosticscompanyfocusedoninflammatorydiseases1.BuildingoffFDA/EMA-approveddiagnosticproduct2.Non-invasiveimagingtargetingCD206receptorsonActivatedMacrophages3.InitialfocusonpersonalizedRheumatoidArthritisDiagnostics4.ProprietaryManocept™platformapplicabletomultiplediseasestatesinbothDiagnostics(Dx)andTherapeutics(Tx)

OurDiagnosticsandTherapeuticsPipeline

NavideaBiopharmaceuticals,Inc.5

RheumatoidArthritisDx

CardiovascularDiseasesDx

SolidTumorsLymphaticMapping,SentinalNodeBiopsyDx(Lymphoseek™)Preclinical/DiscoveryPhase1Phase2Phase3FDA/EMEA-Approved

Anti-InflammatoryTherapeutic

SoldtoCardinalNavideaSeekingPartnerBindingMOUSignedwithJubilant

PlanningPhase2B/Phase3,tbdwithFDA